Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Pharmacy Focus: Oncology Edition : Episode 16
Commentary
Podcast
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
The PALOMA-3 trial showed subcutaneous amivantamab was better than IV among lung cancer patients.
This month, we spoke with Natasha B. Leighl, BSc, MMSc, MD, Medical Oncologist at the Princess Margaret Cancer Centre in Toronto, Canada. Leighl discussed the PALOMA-3 trial results, shared at the American Society of Clinical Oncology 2024 Conference. Leighl noted that the trial compared subcutaneous and intravenous administration of amivantamab for lung cancer.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Videos
Related Content
